Anna J. Lomax

788 total citations
18 papers, 354 citations indexed

About

Anna J. Lomax is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Anna J. Lomax has authored 18 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Anna J. Lomax's work include Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (3 papers) and Drug-Induced Adverse Reactions (2 papers). Anna J. Lomax is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (3 papers) and Drug-Induced Adverse Reactions (2 papers). Anna J. Lomax collaborates with scholars based in Australia and United Kingdom. Anna J. Lomax's co-authors include Catriona M. McNeil, Steven Kao, Judith Lacey, Haryana M. Dhillon, David Levy, Michael Marthick, Neil McGill, Brian Harrisberg, Deme Karikios and Kerwin F. Shannon and has published in prestigious journals such as Journal of Clinical Oncology, Supportive Care in Cancer and Investigational New Drugs.

In The Last Decade

Anna J. Lomax

18 papers receiving 345 citations

Peers

Countries citing papers authored by Anna J. Lomax

Since Specialization

Citations

This map shows the geographic impact of Anna J. Lomax's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna J. Lomax with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna J. Lomax more than expected).

Fields of papers citing papers by Anna J. Lomax

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna J. Lomax. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna J. Lomax. The network helps show where Anna J. Lomax may publish in the future.

Co-authorship network of co-authors of Anna J. Lomax

This figure shows the co-authorship network connecting the top 25 collaborators of Anna J. Lomax. A scholar is included among the top collaborators of Anna J. Lomax based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna J. Lomax. Anna J. Lomax is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	PD‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma 2020 ·Cancer Reports ·(unknown), Anna J. Lomax, Martin Tattersall, David M. Thomas, Geoffrey McCowage, Michael Sullivan, Rooshdiya Z. Karim, Peter P. Luk, Annabelle Mahar, Fiona Bonar, Vivek A. Bhadri	7
2	Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy 2018 ·Supportive Care in Cancer ·David Levy, Haryana M. Dhillon, Anna J. Lomax, Michael Marthick, Catriona M. McNeil, Steven Kao, Judith Lacey	54
3	A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability 2018 ·Supportive Care in Cancer ·Judith Lacey, Anna J. Lomax, Catriona M. McNeil, Michael Marthick, David Levy, Steven Kao, (unknown), Haryana M. Dhillon	34
4	A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers 2018 ·Investigational New Drugs ·Aflah Roohullah, Adam Cooper, Anna J. Lomax, (unknown), Alan Barge, (unknown), (unknown), Jayesh Desai, James R. Whittle, Ben Tran, Paul de Souza, Lisa G. Horvath	23
5	Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management 2018 ·Journal of Skin Cancer ·Anna J. Lomax, (unknown), Robert Y.S. Cheng, Arianne Sweeting, Patricia Lowe, Neil McGill, Nicholas Shackel, Elizabeth L. Chua, Catriona M. McNeil	19
6	Clinical Nurse Consultant Support: Management of Patients With Melanoma Receiving Immunotherapy and Targeted Therapy 2017 ·Clinical journal of oncology nursing ·Anna J. Lomax	2
7	Treatment sequencing and outcomes in synchronous metastatic rectal cancer. 2017 ·Journal of Clinical Oncology ·(unknown), Margaret Lee, Anna J. Lomax, Michael Ng, Mario Guerrieri, Thiru Prasanna, Hui‐Li Wong, Belinda Lee, Joseph McKendrick, Lionel Lim, Suzanne Kosmider, Jeanne Tie, Desmond Yip, Louise Nott, (unknown), (unknown), Peter Gibbs, Rachel Wong	1
8	Immunotherapy‐induced sarcoidosis in patients with melanoma treated with PD‐1 checkpoint inhibitors: Case series and immunophenotypic analysis 2017 ·International Journal of Rheumatic Diseases ·Anna J. Lomax, Helen M. McGuire, Catriona M. McNeil, (unknown), Peter Hersey, Deme Karikios, Kerwin F. Shannon, Sebastian van Hal, (unknown), (unknown), Sandeep K. Gupta, (unknown), Haewon Kim, Barbara Fazekas de St Groth, Neil McGill	84
9	PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma. 2017 ·Journal of Clinical Oncology ·(unknown), Anna J. Lomax, Martin H.N. Tattersall, David M. Thomas, Geoffrey McCowage, Michael Sullivan, Vivek A. Bhadri	7
10	Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician 2017 ·Emergency Medicine Australasia ·Anna J. Lomax, Catriona M. McNeil	23
11	Outcomes of patients with non‐melanoma solid tumours receiving self‐funded pembrolizumab at Chris O'Brien Lifehouse 2016 ·Internal Medicine Journal ·Anna J. Lomax, Jane Beith, Vivek A. Bhadri, Michael Boyer, Peter Grimison, Lisa G. Horvath, Steven Kao, Martin Tattersall, David M. Thomas, Catriona M. McNeil	2
12	Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report 2016 ·Ocular Immunology and Inflammation ·(unknown), Anna J. Lomax, Catriona M. McNeil, Brian Harrisberg	27
13	A randomized controlled trial evaluating the efficacy of a 67% sodium bicarbonate toothpaste on gingivitis 2016 ·International Journal of Dental Hygiene ·Anna J. Lomax, (unknown), (unknown), (unknown), (unknown), (unknown)	10
14	Physical disruption of oral biofilms by sodium bicarbonate: an in vitro study 2015 ·International Journal of Dental Hygiene ·Jonathan Pratten, (unknown), Nicola Mordan, Anna J. Lomax, Nisha Patel, David A. Spratt, (unknown)	24
15	Impact of tumor site on bevacizumab (BEV) efficacy in metastatic colorectal cancer (mCRC). 2014 ·Journal of Clinical Oncology ·Hui‐Li Wong, Kathryn Field, Anna J. Lomax, Mark Tacey, Jeremy Shapiro, Joseph McKendrick, (unknown), Desmond Yip, Louise Nott, Ross Jennens, Gary Richardson, Jeanne Tie, Suzanne Kosmider, Phillip Parente, Lionel Lim, Prasad Cooray, Ben Tran, Jayesh Desai, Rachel Wong, Peter Gibbs	1
16	Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial 2013 ·Journal of bone oncology ·Anna J. Lomax, (unknown), Karen White, Jane Beith, Ehtesham Abdi, A. Broad, Sanjeev Sewak, (unknown), Philip N. Sambrook, Nicholas Pocock, Margaret J. Henry, (unknown), Richard H. Bell	19
17	Spinal cord metastasis in a patient treated with bevacizumab for glioblastoma 2013 ·Targeted Oncology ·Anna J. Lomax, Costas K. Yannakou, Mark Rosenthal	8
18	Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme 2012 ·Journal of Oncology Pharmacy Practice ·Anna J. Lomax, Prue Hill, David M. Ashley	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact